Searchable abstracts of presentations at key conferences in endocrinology

ea0025p311 | Steroids | SFEBES2011

Hepatic 11β-hydroxysteroid dehydrogenase type 1 expression is dynamically related across the liver lobule and is linked to metabolic status

Ahmed Adeeba , Semjonous Nina , Rabbitt Elizabeth , Stewart Paul

Nearly all the functions of the liver display zonation in distribution within each the lobule. Hepatic cortisol availability is controlled by enzymes that regenerate cortisol from inactive cortisone (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1). Dysregulation of hepatic 11β-HSD1 activity has been implicated in insulin resistance. Key processes such as gluconeogenesis are located in the periportal hepatocytes, although current dogma describes hepatic 11&#94...

ea0021p349 | Steroids | SFEBES2009

Urinary steroid metabolite profiling in 11β-HSD1 and H6PDH transgenic mice

Semjonous Nina , Hughes Beverly , Walker Elizabeth , Lavery Gareth , Stewart Paul

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inactive glucocorticoid to their active form (cortisone to cortisol in humans, 11-dehydrocorticosterone (11-DHC) to corticosterone in mice), and is dependent upon the presence of cofactor NADPH generated by the enzyme hexose-6-phosphate (H6PDH) for its activity. The 11β-HSD1/H6PDH system is implicated in the pathogenesis of the metabolic syndrome by generating tissue specific glucocorticoid excess. The ...

ea0025p166 | Diabetes, metabolism and cardiovascular | SFEBES2011

Lack of beneficial metabolic profile in liver-specific 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) knockout mice

Lavery Gareth , Rabbitt Elizabeth , Zielinszka Agnieszka , Huges Beverley , Semjonous Nina , Saqib Khalid , Morgan Stuart , Gathercole Laura , Walker Elizabeth , Stewart Paul

In humans glucocorticoid (GC) excess can promote hepatic glucose and triglyceride production contributing to obesity, fatty liver and diabetes. 11β-HSD1 activates GCs (11-DHC to corticosterone in mice), thereby increasing tissue concentrations. The liver has the highest 11β-HSD1 activity, and its inhibition has emerged as a therapeutic option. To investigate this we generated 11β-HSD1 liver-specific knockouts (HSD1LKO) and examined GC metabolism and responses to...